Copegus
Copegus is indicated for chronic hepatitis C to mitigate viral loads, utilized to support liver health and to address disease progression.
Strengths: 100mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Rebetol
- Therapeutic class
Antiviral
- Pharmacological class
Nucleoside Analogue
- Contraindications
pregnancy; severe heart disease; severe renal impairment; haemoglobinopathies
- Minor side effects
fatigue; headache; insomnia; nausea
- Moderate side effects
anaemia; dry skin; rash
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Roche
- Onset Time
1–2 hours
- Duration
24 hours
- Storage instructions
Store at room temperature below 30°C.
- Drug interactions
didanosine; azathioprine; stavudine
- Age restrictions
Adults.
Precautions and warnings
requires strict pregnancy prevention protocols for both sexes; monitor blood counts regularly; risk of haemolytic anaemia
Serious side effects
haemolytic anaemia — requires immediate medical attention; severe depression — requires immediate medical attention
Patient summary
Copegus is indicated for chronic hepatitis C to mitigate viral loads, utilized to support liver health and to address disease progression.
Mechanism of action
Copegus acts as a broad-spectrum antiviral agent. It interferes with the replication of viral RNA by mimicking natural nucleosides, thereby preventing the virus from effectively multiplying within the liver cells.
Pregnancy and breastfeeding
Pregnancy: Strict contraindication. Must not be used during pregnancy. Breastfeeding: Avoid use.
Copegus
Copegus is indicated for chronic hepatitis C to mitigate viral loads, utilized to support liver health and to address disease progression.
Editorial Notes
- Active ingredient(s): Ribavirin
- Listed indication(s): Chronic Hepatitis C
Available option
- 30 tablets - 100 mg705-100-mg-2522